IOVANCE BIOTHERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.89M, a 17.91% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $11.67M, a 49.19% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $11.69M, a 61.65% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $11.75M, a 61.83% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $60.90M, a 45.08% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $110.88M, a 77.05% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $62.63M, a 25.47% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $84.02M, a 20.44% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.89M 10-Q · filed 2026-08-06 | $23.56M 10-Q · filed 2026-08-06 | $35.25M derived: sum of 3 quarters · filed 2026-08-06 | $47.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.67M 10-Q · filed 2026-05-07 | $23.36M derived: sum of 2 quarters · filed 2026-05-07 | $35.11M derived: sum of 3 quarters · filed 2026-05-07 | $49.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $23.44M derived: sum of 2 quarters · filed 2026-02-24 | $37.93M derived: sum of 3 quarters · filed 2026-08-06 | $60.90M 10-K · filed 2026-02-24 |
| 2025-09-30 | $11.75M 10-Q · filed 2025-11-06 | $26.23M derived: sum of 2 quarters · filed 2026-08-06 | $49.21M 10-Q · filed 2025-11-06 | $79.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.48M 10-Q · filed 2026-08-06 | $37.45M 10-Q · filed 2026-08-06 | $67.94M derived: sum of 3 quarters · filed 2026-08-06 | $98.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $22.97M 10-Q · filed 2026-05-07 | $53.46M derived: sum of 2 quarters · filed 2026-05-07 | $84.24M derived: sum of 3 quarters · filed 2026-05-07 | $116.07M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $61.27M derived: sum of 2 quarters · filed 2026-02-24 | $93.10M derived: sum of 3 quarters · filed 2026-02-24 | $110.88M 10-K · filed 2026-02-24 |
| 2024-09-30 | $30.79M 10-Q · filed 2025-11-06 | $62.62M derived: sum of 2 quarters · filed 2025-11-06 | $80.39M 10-Q · filed 2025-11-06 | $94.79M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $31.83M 10-Q · filed 2025-08-07 | $49.60M 10-Q · filed 2025-08-07 | $64.00M derived: sum of 3 quarters · filed 2026-02-24 | $79.82M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $17.77M 10-Q · filed 2025-05-08 | $32.17M derived: sum of 2 quarters · filed 2026-02-24 | $47.99M derived: sum of 3 quarters · filed 2026-02-24 | $64.73M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $30.22M derived: sum of 2 quarters · filed 2026-02-24 | $46.96M derived: sum of 3 quarters · filed 2026-02-24 | $62.63M 10-K · filed 2026-02-24 |
| 2023-09-30 | $15.82M 10-Q · filed 2024-11-07 | $32.56M derived: sum of 2 quarters · filed 2024-11-07 | $48.23M 10-Q · filed 2024-11-07 | $67.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $16.74M 10-Q · filed 2024-08-08 | $32.41M 10-Q · filed 2024-08-08 | $51.91M derived: sum of 3 quarters · filed 2025-02-27 | $71.69M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $15.66M 10-Q · filed 2024-05-09 | $35.17M derived: sum of 2 quarters · filed 2025-02-27 | $54.95M derived: sum of 3 quarters · filed 2025-02-27 | $77.42M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $19.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $39.29M derived: sum of 2 quarters · filed 2025-02-27 | $61.76M derived: sum of 3 quarters · filed 2025-02-27 | $84.02M 10-K · filed 2025-02-27 |
| 2022-09-30 | $19.78M 10-Q · filed 2023-11-07 | $42.25M derived: sum of 2 quarters · filed 2023-11-07 | $64.51M 10-Q · filed 2023-11-07 | $83.62M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $22.47M 10-Q · filed 2023-08-08 | $44.73M 10-Q · filed 2023-08-08 | $63.84M derived: sum of 3 quarters · filed 2024-02-28 | $83.14M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $22.27M 10-Q · filed 2023-05-10 | $41.37M derived: sum of 2 quarters · filed 2024-02-28 | $60.67M derived: sum of 3 quarters · filed 2024-02-28 | $75.09M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $19.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $38.41M derived: sum of 2 quarters · filed 2024-02-28 | $52.82M derived: sum of 3 quarters · filed 2024-02-28 | $69.77M 10-K · filed 2024-02-28 |
| 2021-09-30 | $19.31M 10-Q · filed 2022-11-03 | $33.72M derived: sum of 2 quarters · filed 2022-11-03 | $50.66M 10-Q · filed 2022-11-03 | $60.78M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $14.41M 10-Q · filed 2022-08-04 | $31.36M 10-Q · filed 2022-08-04 | $41.48M derived: sum of 3 quarters · filed 2023-02-28 | $52.18M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $16.94M 10-Q · filed 2022-05-05 | $27.06M derived: sum of 2 quarters · filed 2023-02-28 | $37.77M derived: sum of 3 quarters · filed 2023-02-28 | $48.30M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $10.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $20.83M derived: sum of 2 quarters · filed 2023-02-28 | $31.36M derived: sum of 3 quarters · filed 2023-02-28 | $40.77M 10-K · filed 2023-02-28 |
| 2020-09-30 | $10.71M 10-Q · filed 2021-11-04 | $21.24M derived: sum of 2 quarters · filed 2021-11-04 | $30.66M 10-Q · filed 2021-11-04 | $36.06M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $10.54M 10-Q · filed 2021-08-05 | $19.95M 10-Q · filed 2021-08-05 | $25.36M derived: sum of 3 quarters · filed 2022-02-24 | $31.95M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $9.41M 10-Q · filed 2021-05-06 | $14.82M derived: sum of 2 quarters · filed 2022-02-24 | $21.42M derived: sum of 3 quarters · filed 2022-02-24 | $27.84M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $12.01M derived: sum of 2 quarters · filed 2022-02-24 | $18.43M derived: sum of 3 quarters · filed 2022-02-24 | $24.28M 10-K · filed 2022-02-24 |
| 2019-09-30 | $6.60M 10-Q · filed 2020-11-05 | $13.02M derived: sum of 2 quarters · filed 2020-11-05 | $18.87M 10-Q · filed 2020-11-05 | $24.05M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $6.43M 10-Q · filed 2020-08-06 | $12.27M 10-Q · filed 2020-08-06 | $17.46M derived: sum of 3 quarters · filed 2021-02-25 | $22.97M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $5.85M 10-Q · filed 2020-05-05 | $11.03M derived: sum of 2 quarters · filed 2021-02-25 | $16.55M derived: sum of 3 quarters · filed 2021-02-25 | $21.77M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $10.70M derived: sum of 2 quarters · filed 2021-02-25 | $15.92M derived: sum of 3 quarters · filed 2021-02-25 | $20.03M 10-K · filed 2021-02-25 |
| 2018-09-30 | $5.52M 10-Q · filed 2019-11-04 | $10.74M derived: sum of 2 quarters · filed 2019-11-04 | $14.84M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $5.22M 10-Q · filed 2019-08-01 | $9.33M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $4.10M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $11.97M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $18.90M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $15.78M 10-Q · filed 2016-11-04 | |||
| 2015-12-31 | $6.75M 10-K · filed 2018-03-12 | |||
| 2014-12-31 | $2.56M 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |